Source comparison
Tesamorelin Side Effects: Clinical Research vs Patient Experience Comparison
Injection Site Reactions 12–18% sustained Weeks 1–8 (peak week 2–4) Persists in 40%, resolves spontaneously in 60% by week 24 <1% Most tolerable with site rotation; rarely warrants stopping therapy Arthralgias (Joint Pain) 8–12% Weeks 8–16 (correlates with pea
This comparison does not assign a generated winner or score.
- Injection Site Reactions
- 12–18% sustained
- Weeks 1–8 (peak week 2–4)
- Persists in 40%, resolves spontaneously in 60% by week 24
- <1%
- Most tolerable with site rotation; rarely warrants stopping therapy
- Arthralgias (Joint Pain)
- 8–12%
- Weeks 8–16 (correlates with peak IGF-1)
- Resolves spontaneously in 60–70% by week 24 even with continued use
- 2–3%
- Suggests adaptive response rather than progressive pathology; persistent cases typically have pre-existing joint disease
- Peripheral Edema
- 5–8%
- Weeks 4–12
- Rarely resolves during continued therapy; reverses within 7–10 days of cessation
- 1–2%
- Responds to low-dose diuretics if bothersome; not a safety concern
- Carpal Tunnel Syndrome
- 2–4%
- Weeks 12–20
- Fully reversible within 4–8 weeks of stopping in 92% of cases
- 3–4% (highest discontinuation driver)
- Patients with baseline median nerve compression face 3–4× higher risk; electrodiagnostic screening advisable
- Transient Hyperglycemia
- 15–20% (diabetics 30–35%)
- Weeks 4–16
- Stabilizes by week 20–24; HbA1c changes <0.2% in most cases
- Requires monitoring but rarely necessitates discontinuation; manageable with diabetes medication adjustment
- IGF-1 Elevation >2.5× Baseline
- 6–8%
- Weeks 8–12
- Normalizes within 4–8 weeks of dose reduction or cessation
- 0% (managed with dose adjustment)
- No documented cancer signal in trials up to 26 months; theoretical concern drives monitoring